

Technology Appraisal Committee C Interests Register

Topic: Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]

Publication Date: 07/06/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee member	Direct - financial	Michael Chambers has participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and has helped co-ordinate a (University of Utrecht) training programme in Real World Evidence for Roche, which did not involve consideration of any Roche products. Both Pfizer and Roche are manufacturers of possible comparator therapies.		05/07/2022 16/08/22		It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee member	Direct - financial	Dr Richard Nicholas has carried out paid advisory boards with Roche and Novartis in an unrelated area - multiple sclerosis.		05/07/2022 22/08/22		It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
Dr Graham Collins	Clinical expert	Direct - financial	Dr Graham Collins has received honoraria for		05/07/2022		It was agreed his declaration would not

			speaker and advisory work from Kite / Gilead.		06/09/22		prevent Dr Collins from providing expert advice to the committee.
Dr Tobias Menne	Clinical expert	Direct - financial	Dr Tobias Menne has received travel grants from Amgen, Jazz, Pfizer, Bayer, Kyowa Kirin, Celgene, Kite/Gilead, Janssen, and Takeda, honoraria for advisory board meetings from Kite/Gilead, Amgen, Novartis, Pfizer, Celgene/BMS, Daiichi Sankyo, Atara, Roche, Janssen, and honoraria for lectures from Kite/Gilead, Takeda, Janssen, Roche, Servier, Novartis, Celgene and Research funding from Janssen, Astra Zeneca, Novartis.		17/11/2021 06/09/22		It was agreed his declaration would not prevent Dr Menne from providing expert advice to the committee.